UnitedHealthcare carrier screening Coverage Update

Coverage Criteria

Reproductive Carrier Screening Coverage

Covered when ALL of the following are met:

General reproductive carrier screening (small panels): Reproductive Carrier Screening Panels of up to six genes are proven and medically necessary.<=6 genes

Expanded reproductive carrier screening (up to 15 genes) with criteria: Reproductive Carrier Screening Panels of up to 15 genes are medically necessary when the individual and/or their reproductive partner meet at least one of the following: (1) Ashkenazi Jewish ancestry (at least one parent or grandparent of Ashkenazi Jewish descent); or (2) a biological first- or second-degree relative affected by one or more of the conditions evaluated by the panel.<=15 genes AND (AJ ancestry OR affected first/second-degree relative)

Panels not covered: Reproductive Carrier Screening Panels comprised of 16 or more genes are unproven and not medically necessary.>=16 genes

Guideline-consistent panel

Coverage considerations informed by guideline-aligned panel design:

Conservative panel inclusion (guideline-consistent): Panel includes conditions meeting conservative thresholds consistent with professional guidance (e.g., carrier frequency ≥ 1/100, well-defined phenotype, detrimental impact on quality of life, and prenatal diagnosability).carrier frequency >= 1/100

ACOG proposed ≥1/100 and ClinGen curation supports gene-disease validity

Liberal threshold panel

Alternative (more liberal) panel considered acceptable by some analyses:

Liberal panel inclusion: Panel includes conditions meeting more liberal frequency thresholds (for example, carrier frequency ≥ 1/200) to expand detection of carriers and at‑risk couples.carrier frequency >= 1/200

Johansen Taber analysis identified 74 conditions meeting liberal thresholds

Laboratory reporting and validity

Panels and laboratory reporting/prioritization considerations:

Laboratory panel transparency and validity: Laboratory must provide transparent gene content and evidence of gene–disease validity and report metrics used to calculate detection rate and residual/recurrence risk to support clinical interpretation.N/A

Significant variation in panel content and detection metrics has been reported across commercial panels; laboratories should document methods for DR/RR calculation

Clinical impact of panel size: Larger panels identify more carriers but may include conditions with variable penetrance or mild phenotypes and increase clinical workload; panel choice should balance yield with clinical utility and follow-up capacity.N/A

Studies show positivity rates and carrier yield increase with panel size (examples: 23-, 274-gene panels)

Professional society recommendations and contextual criteria

Coverage-relevant recommendations from professional societies and evidence summaries include:

ACOG recommendations: ACOG: offer hemoglobinopathy testing to all individuals planning pregnancy or at first prenatal visit if not previously tested; offer carrier screening for cystic fibrosis and spinal muscular atrophy and screening for thalassemias/hemoglobinopathies to all pregnant or considering pregnancy. If considering ECS, include disorders with carrier frequency >1/100, well-defined severe phenotype, prenatal diagnosability, and exclude adult-onset conditions.

ACMG tiered approach: ACMG: adopt a tiered carrier screening approach (Tier 1: CF + SMA + risk-based; Tier 2: ≥1/100; Tier 3: ≥1/200 including X-linked) and offer Tier 3 screening to all pregnant patients and those planning pregnancy; reserve broader (Tier 4) testing for consanguinity or family/personal history indications.

NSGC conditional recommendation: NSGC: conditionally recommends offering ECS to all individuals considering reproduction, pregnant individuals, and partners, with shared decision-making and attention to access and education barriers.

Carrier screening performed for non-reproductive indications is considered unproven and not medically necessary. The policy explicitly lists “Carrier Screening for all other indications” as unproven and not medically necessary, and recommends that reproductive carrier screening panels include testing for CFTR and SMN1 when applicable.

The available excerpts do not enumerate specific excluded panel sizes or named genes beyond broader policy thresholds, but multiple studies note variability in panel composition and that some panels omit certain conditions (for example, one ECS panel did not include α-thalassemia or MSUD1A). This lack of standardization across laboratories affects comparability of carrier rates between panels and should be considered when evaluating test selection and claims.

The RCOG scientific impact paper concludes there is insufficient evidence to recommend routine testing of all prospective parents. RCOG emphasizes the current lack of standardization among expanded carrier screening (ECS) panels and recommends providers understand panel composition and ensure interpretation is performed by clinicians with appropriate genetics expertise prior to routine universal use.

The policy identifies reproductive carrier screening panels composed of 16 or more genes as unproven and not medically necessary. This NMN stance for larger panels is supported by evidence showing that positive rates and panel content vary widely as panel size increases, and that larger panels may identify many findings of uncertain clinical utility that can burden clinical workflow.

Although the document does not contain an explicit additional NMN statement in the provided excerpts beyond the 16+ gene threshold, studies raise concerns about the clinical workflow burden and unclear utility of very large genomic sequencing–based panels (reporting hundreds of conditions). These operational and interpretive challenges are noted as factors that may limit clinical usefulness of very large panels.

Covered Indications

Reproductive carrier screening for individuals planning pregnancy or currently pregnant; Ashkenazi Jewish-specific panels when ancestry or family history criteria are met.

Covered indications — Reproductive carrier screening when ALL of the following apply:

Indication: planning pregnancy or currently pregnant: Carrier screening is indicated for individuals who are planning pregnancy or who are currently pregnant to identify carrier status for autosomal recessive and X‑linked conditions.

ACOG recommends CF, SMA, and hemoglobinopathy screening for all pregnant or considering pregnancy (see ACOG guidance)

Ashkenazi Jewish-specific panel: Individuals of Ashkenazi Jewish descent (at least one parent or grandparent of AJ descent) qualify for expanded AJ-targeted panels that include AJ‑prevalent disorders (examples: Tay‑Sachs, Canavan disease, CF, SMA, familial dysautonomia, Bloom, Fanconi anemia, Niemann‑Pick, Gaucher, mucolipidosis IV, MSUD, Joubert).

AJ panel examples listed in source

Family history triggers expanded panel:

Eligibility Requirements

No top-level eligibility requirement nodes are specified in this section.

Many published studies excluded individuals with a positive family or personal history when evaluating expanded carrier screening (ECS). ECS is also used in cohorts both with and without family history, so there is no single universal eligibility rule across studies; clinical judgment, ancestry, and family history are commonly considered when selecting panels.

As above, multiple study cohorts excluded individuals with family or personal history for analytic purposes. In practice, ECS may be offered regardless of family history, and some covered indications in this policy specifically allow expanded panels when ancestry or affected first- or second-degree relatives meet policy criteria.

No top-level eligibility requirement nodes are specified in this section.

Coding

Applicable Procedure CodesCPT

0400U	Obstetrics (expanded carrier screening), 145 genes by next generation sequencing, fragment analysis and multiplex ligation dependent probe amplification, DNA, reported as carrier positive or negative.
81412	Ashkenazi Jewish associated disorders genomic sequence analysis panel, must include sequencing of at least 9 genes (e.g., ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, SMPD1).
81443	Genetic testing for severe inherited conditions genomic sequence analysis panel, must include sequencing of at least 15 genes (examples listed).
81479	Unlisted molecular pathology procedure.

Applicable Procedure Codes (raw group)mixed

0400U	Obstetrics (expanded carrier screening), 145 genes by next generation sequencing, fragment analysis and multiplex ligation dependent probe amplification, DNA, reported as carrier positive or negative.
81412	Ashkenazi Jewish associated disorders (e.g., Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1.
81443	Genetic testing for severe inherited conditions (e.g., cystic fibrosis, Ashkenazi Jewish-associated disorders [e.g., Bloom syndrome, Canavan disease, Fanconi anemia type C, mucolipidosis type VI, Gaucher disease, Tay-Sachs disease], beta hemoglobinopathies, phenylketonuria, galactosemia), genomic sequence analysis panel, must include sequencing of at least 15 genes (e.g., ACADM, ARSA, ASPA, ATP7B, BCKDHA, BCKDHB, BLM, CFTR, DHCR7, FANCC, G6PC, GAA, GALT, GBA, GBE1, HBB, HEXA, IKBKAP, MCOLN1, PAH).
81479	Unlisted molecular pathology procedure.

Carrier frequency thresholds referenced

ACOG suggested thresholdCarrier frequency ≥ 1/100 (ACOG proposal correlating with disease incidence ~1/40,000)

ACMG tier referenceACMG Tier 2 includes conditions with carrier frequency ≥ 1/100 (Tiered system includes Tier 3 ≥ 1/200)

Use in panel designJohansen Taber analysis: 37 conditions met conservative (≥1/100) threshold aligning with guideline-based panel design

ACOG carrier frequency threshold

ACOG carrier frequency criterionCarrier frequency ≥ 1/100 is a consensus-driven criterion for disorders considered for ECS panels (ACOG Committee Opinion)

Associated ACOG guidanceACOG recommends panels include conditions with well-defined phenotype, detrimental impact on quality of life, early onset, and prenatal diagnosability in addition to frequency threshold

Provider Actions and Operational Notes

Prior Authorization

Code reference and authorization note

The following codes are provided for reference only. Listing of a code in this policy does not imply that the service described by the code is a covered or non‑covered benefit, nor does inclusion guarantee payment. Verify coding and coverage rules against the member specific benefit plan and any applicable federal or state mandates before submitting prior authorization or claims.

Code lists in this policy are not all‑inclusive and are for informational use only.
Inclusion of a code does not imply a right to reimbursement or guarantee claim payment.

Prior Authorization

Verify prior authorization per member plan

Prior authorization requirements are determined by the member specific benefit plan. Confirm whether prior authorization (PA) or other administrative approval is required before ordering testing.

Verify PA and medical necessity per the member’s benefit document and UnitedHealthcare tools before testing.
If PA is required, submit supporting medical records and documentation to demonstrate criteria are met.

Not Covered

The policy states that Carrier Screening for all other indications (non-reproductive) and reproductive carrier screening panels of 16 or more genes are not covered because they are unproven and not medically necessary. Providers should expect these test types to be ineligible for coverage under the stated criteria.

There is no explicit exhaustive list of not-covered tests in the provided excerpts. The literature and policy note variability and lack of consensus on which genes to include in commercial panels and raise concerns about inclusion of mild or adult-onset conditions that may have limited reproductive utility, which can inform coverage determinations.

RCOG does not support routine universal screening of all prospective parents due to insufficient evidence. This perspective supports cautious use of routine panel testing across entire populations and may influence what is considered not covered on a universal basis.

Background and Rationale

Carrier screening identifies individuals without symptoms who may carry variants that can be transmitted to offspring. Next-generation sequencing enables multi-gene panels and expanded carrier screening (ECS), but professional societies (ACOG, ACMG, NSGC) emphasize targeted inclusion criteria and the importance of genetic counseling. ACOG specifically recommends offering screening for cystic fibrosis and spinal muscular atrophy and hemoglobinopathy testing to all individuals planning pregnancy or at first prenatal visit if not previously tested.

Definitions

Carrier Screening

DefinitionGenetic testing performed on an individual without symptoms to determine whether that individual may have a genetic variant associated with a disorder that could be passed to biological children.

Typical useOffered preconception or prenatally to identify carrier status for autosomal recessive and X-linked conditions.

Relation to ECSExpanded (pan-ethnic) carrier screening applies this testing across dozens to hundreds of genes regardless of self-reported ethnicity.

First-Degree Relative

DefinitionParents, siblings, and children.

Coverage relevanceA biological first‑degree relative affected by a condition evaluated by the panel can qualify an individual for expanded panel coverage (up to 15 genes).

Revision History

2026-01-01template_updateLatest

Created shared policy version to support application to Oxford plan membership and archived prior policy versions (2025T0586R and LABORATORY 021.16)

OpenPayer

Carrier Testing Panels for Genetic Diseases